Talis Biomedical Corporation
TLIS · OTC
12/31/2023 | 12/31/2022 | 12/31/2021 | 12/31/2020 | |
|---|---|---|---|---|
| Market Cap | $0 | $0 | $0 | $0 |
| - Cash | $0 | $0 | $0 | $0 |
| + Debt | $0 | $0 | $0 | $0 |
| Enterprise Value | -$0 | -$0 | -$0 | -$0 |
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | -88.7% | – | -100% | – |
| Gross Profit | $0 | -$0 | -$0 | $0 |
| % Margin | 90% | -129.8% | – | 87.4% |
| EBITDA | -$0 | -$0 | -$0 | -$0 |
| % Margin | -16,030.3% | -2,776.9% | – | -820.6% |
| Net Income | -$0 | -$0 | -$0 | -$0 |
| % Margin | -15,050.2% | -3,094.5% | – | -832.7% |
| EPS Diluted | -34.12 | -63.65 | -126.13 | -314.06 |
| % Growth | 46.4% | 49.5% | 59.8% | – |
| Operating Cash Flow | -$0 | -$0 | -$0 | -$0 |
| Capital Expenditures | -$0 | -$0 | -$0 | -$0 |
| Free Cash Flow | -$0 | -$0 | -$0 | -$0 |